Alivus Life Sciences Delivers Strong Q4FY25 Performance with 21% YoY Revenue Growth, EBITDA Margins at 32.1% YoY
Alivus Life Sciences Limited, a leading developer and manufacturer of high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, announced its financial results for the quarter and year ended March 31, 2025. The company reported a 21.1% YoY growth in Q4FY25 revenue, reaching Rs. 6,496 Mn. For FY25, revenue from operations was Rs. 23,869 Mn, a growth of 4.5% YoY. EBITDA for Q4FY25 was at Rs. 2,085 Mn, a growth of 44.2% YoY. EBITDA margins were at 32.1%, up 520 bps YoY. The company recorded PAT of Rs. 4,857 Mn with PAT margins of 20.3% for FY25. Alivus Life Sciences generated a strong free cash flow of Rs. 2,328 Mn leading to Cash and Cash Equivalents of Rs. 5,487 Mn as of 31 March 2025.
Key Highlights
- Q4FY25 revenue grew by 21.1% YoY to Rs. 6,496 Mn
- FY25 revenue reached Rs. 23,869 Mn, a growth of 4.5% YoY
- Q4FY25 EBITDA grew by 44.2% YoY to Rs. 2,085 Mn
- EBITDA margins stood at 32.1% in Q4FY25, up 520 bps YoY
- FY25 PAT was Rs. 4,857 Mn with a margin of 20.3%
- Generated strong free cash flow of Rs. 2,328 Mn in FY25